Arimoclomol demonstrated a marked and clinically meaningful dose-dependent reduction in liver and spleen size
Data supports Orphazyme's intention to proceed with pivotal stage clinical development in Gaucher disease
PR Newswire
LOS ANGELES, June 29, 2020